Geovax Labs Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0-100.0% YoYTTM through 30 Jun 2026
Net Income -$20.4MTTM through 30 Jun 2026
Free Cash Flow -$18.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Operating Margin | -869.3% |
| Net Margin | -861.9% |
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.74x
Net Debt-$3.1Mnet cash position
Cash & Equivalents$3.1M
Quality Metrics
Altman Z-Score-61.93
Piotroski F-Score3 / 9
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2025: $2.5M
Diluted EPSFY2025: $-22.40
Dividend
No dividend
Capital Allocation
R&D Spend$15.1M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biotechnology Research and Development | $2.5M | -37.1% | View detailsPrioritizing resources on GEO-MVA and Gedeptin following the strategic discontinuation of the GEO-CM04S1 COVID-19 vaccine program in mid-2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.